KEYNOTE-921: Phase III Study of Pembrolizumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer
Year: 2021
Type: article
Abstract: Despite recent advances, treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after next-generation hormonal agents (NHAs) are limited and provide only modest survival benefit. Thus, an unmet need remains for mCRPC patients after treatment with targeted endocrine therapy or NHA therapy. Pembrolizumab, a humanized monoclonal antibody for PD-1, has been found to have activity as monotherapy in patients with mCRPC and as combination therapy in a Phase Ib/II study with docetaxel and prednisone/prednisolone for patients previously treated with enzalutamide or abiraterone acetate. The aim of the randomized, double-blind, Phase III KEYNOTE-921 study is to evaluate the efficacy and safety of pembrolizumab plus docetaxel in patients with mCRPC who were previously treated with an NHA. Clinical trial registration: NCT03834506 (ClinicalTrials.gov)
Source: Future Oncology
Institutions: Yale University, Smilow Cancer Hospital, Hôpital Foch, Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Institut Català d'Oncologia, Medical University of Vienna, University of Colorado Anschutz, Merck & Co., Inc., Rahway, NJ, USA (United States), Université Paris-Saclay, Institut Gustave Roussy
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W3169646186